VivoSim Labs Inc. announced the appointment of JCBio as its authorized distributor in Korea and Tekon Biotech as its authorized distributor in China for its NAMKind™ toxicology services focused on liver and small intestine screening. These distribution agreements will provide pharmaceutical and biotechnology organizations in Korea and China with access to VivoSim's human-based New Approach Methodologies (NAMs) for preclinical safety assessment. The company aims to offer decision-ready toxicology data with a targeted 30-day turnaround time per study, supporting faster and earlier de-risking of drug development pipelines in the Asia-Pacific region.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VivoSim Labs Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9644969-en) on January 29, 2026, and is solely responsible for the information contained therein.